IN8bio, Inc. (INAB)
|Net Income (ttm)||-8.23M|
IN8bio was founded to advance a pipeline of treatment options for glioblastoma [GBM] and acute leukemia using 'allogeneic, autologous and genetically modified gamma-delta T cells.
IN8bio, a Phase 1 biotech developing allogeneic T cell therapies for cancer and solid tumors, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
IN8bio, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).
IN8bio is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Gamma-delta T cells are naturally occurring cells in the human immune system that recognize and kill cancerous cells, while possessing a tumor recognition mechanism that protects healthy tissue. Gamma-delta T cells embody properties of both the innate and adaptive immune systems, which allows for them to serve as a funct... [Read more...]
|IPO Date |
|Stock Exchange |
|Ticker Symbol |